Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.38 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 3/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1479671 | 0.78 | ZDHHC7 (0.39) | GPR84CA2CA1FFAR1 | |
| Hexane SCHEMBL6816825 | 0.76 | ALDH1A1 (0.42) | GPR84PPARD | |
| Hexane SCHEMBL3117746 | 0.76 | ALDH1A1 (0.42) | GPR84PPARD | |
| SCHEMBL4347772 | 0.76 | GPR84 (0.44) | GPR84CA2FFAR1MAPTLCK | |
| SCHEMBL5999707 | 0.75 | TSHR (0.44) | GPR84CA2FFAR1MAPTFDPS | |
| SCHEMBL27495922 | 0.74 | GPR84 (0.44) | GPR84CA1FFAR1MAPTFFAR4 | |
| SCHEMBL9365266 | 0.74 | LMNA (0.50) | GPR84CA2CA1FFAR1MAPT | |
| Hexane SCHEMBL299439 | 0.74 | LMNA (0.50) | GPR84CA2CA1FFAR1MAPT | |
| Hexane SCHEMBL8676368 | 0.74 | LMNA (0.50) | GPR84CA2CA1FFAR1MAPT | |
| Hexane SCHEMBL2810416 | 0.74 | LMNA (0.50) | GPR84CA2CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105315242-A | Removal method of colloid and pigment in crude paclitaxel product | CHONGQING ZHENYUAN HONGDOUSHAN DEV CO LTD | 2016-02-10 | — | — | CN | claimed |
| EP-2753607-B1 | BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY AND ASSOCIATES INC (US) | 2016-04-13 | — | — | EP | disclosed |
| CN-105315242-A | Removal method of colloid and pigment in crude paclitaxel product | CHONGQING ZHENYUAN HONGDOUSHAN DEV CO LTD | 2016-02-10 | — | — | CN | disclosed |
| WO-2013036748-A1 | BICYCLO[6.1.0]NON-4-YNE REAGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY, LANA, L. (US) | 2013-03-14 | — | — | WO | disclosed |
| US-20130066063-A1 | BICYCLO[6.1.0]NON-4-YNE REGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | BERRY AND ASSOCIATES, INC. | 2013-03-14 | — | — | US | disclosed |
| EP-1181299-B1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20020193320-A1 | C-2 modified erythromycin derivatives | ABBOTT LABORATORIES | 2002-12-19 | — | — | US | disclosed |
| US-6355620-B1 | ANTIBIOTIC ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES | 2002-03-12 | — | — | US | disclosed |
| EP-1181299-A1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | Abbott Laboratories (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000069875-A9 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LAB (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2000069875-A1 | C-2 MODIFIED ERYTHROMYCIN DERIVATIVES | ABBOTT LABORATORIES (US) | 2000-11-23 | — | — | WO | disclosed |
| US-6090332-A | Process of changing the refractive index of a composite containing a polymer and a compound having large dipole moment and polarizability and applications thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066063-A1 | BICYCLO[6.1.0]NON-4-YNE REGENTS FOR CHEMICAL MODIFICATION OF OLIGONUCLEOTIDES | NSUN2, BCDIN3D, YBX1 | GPR84 3659/4885CA2 3491/4885CA1 3165/4885 |
| US-20020193320-A1 | C-2 modified erythromycin derivatives | CYP2D6, CYP1A2, CYP2B6 | GPR84 3395/4885CA2 1235/4885CA1 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.